197 related articles for article (PubMed ID: 22257580)
1. Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination.
Kim KP; Lim KS; Kim BH; Shin HS; Cho JY; Shin SG; Jang IJ; Yu KS
Int J Clin Pharmacol Ther; 2012 Feb; 50(2):142-9. PubMed ID: 22257580
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers.
Gu N; Kim BH; Rhim H; Chung JY; Kim JR; Shin HS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2010 Jul; 32(7):1408-18. PubMed ID: 20678687
[TBL] [Abstract][Full Text] [Related]
5. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
6. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
7. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers.
Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG
Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181
[TBL] [Abstract][Full Text] [Related]
8. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
[TBL] [Abstract][Full Text] [Related]
9. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
10. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes.
Kim JD; Park CY; Cha BY; Ahn KJ; Kim IJ; Park KS; Lee HW; Min KW; Won JC; Chung MY; Kim JT; Kang JG; Park SW
Clin Ther; 2018 May; 40(5):752-761.e2. PubMed ID: 29729957
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects.
Huh KY; Kim E; Lee H; Jeon I; Suh H; Lee J; Lee Y; Yu KS; Lee S
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):207-213. PubMed ID: 32579298
[TBL] [Abstract][Full Text] [Related]
13. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects.
Cho HY; Yoon H; Lim YC; Lee YB
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):770-9. PubMed ID: 19954716
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets.
Ghim JL; Phuong NTT; Kim MJ; Kim EJ; Song GS; Ahn S; Shin JG; Kim EY
Drug Des Devel Ther; 2019; 13():1623-1632. PubMed ID: 31190741
[No Abstract] [Full Text] [Related]
16. Replicate study design in bioequivalency assessment, pros and cons: bioavailabilities of the antidiabetic drugs pioglitazone and glimepiride present in a fixed-dose combination formulation.
Karim A; Zhao Z; Slater M; Bradford D; Schuster J; Laurent A
J Clin Pharmacol; 2007 Jul; 47(7):806-16. PubMed ID: 17463215
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
Choi HG; Jeon JY; Im YJ; Kim Y; Jang H; Kang S; Kim KH; Chae SW; Lee SY; Kim MG
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):55-63. PubMed ID: 24290415
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Cho YS; Lee SH; Lim HS; Bae KS
J Korean Med Sci; 2018 Oct; 33(41):e258. PubMed ID: 30288156
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
He YL; Paladini S; Sabia H; Campestrini J; Zhang Y; Leon S; Ligueros-Saylan M; Jarugula V
Int J Clin Pharmacol Ther; 2008 May; 46(5):259-67. PubMed ID: 18538112
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Bioequivalency and Pharmacokinetic Parameters for Two Formulations of Glimepiride 1-mg in Chinese Subjects.
Ju G; Yan K; Xu Y; Chen S; Zheng Z; Qiu W
Drug Des Devel Ther; 2020; 14():2637-2644. PubMed ID: 32753845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
